Hindustan Copper market cap crosses ₹50,000 crore as stock gains for seventh day

At the day’s high, shares of Hindustan Copper had gained 48% during this seven-day gaining streak, with its market capitalization nearing the mark of ₹50,000 crore.

At the day’s high, shares of Hindustan Copper had gained 48% during this seven-day gaining streak, with its market capitalization nearing the mark of ₹50,000 crore.

Peter Maguire, Chief Executive Officer of trading.com, is constructive on gold and expects prices to rise toward the $4,745 level. He said the outlook is supported by a weakening US dollar and rapidly evolving geopolitical developments involving Russia, Ukraine, and…

The rupee fell 5 paise to 89.95 against the US dollar in early trade on Monday amid foreign fund outflows and a muted opening in the domestic equity markets.

IRDAI fined Reliance General Insurance ₹1 crore for 2021 violations. The insurer must report actions and may appeal to the Appellate Tribunal.

Technology and regulatory support have democratised investing, bringing markets closer to the masses. Mobile platforms, UPI payments, and seamless onboarding have made SIPs as easy as online shopping. Ahead, innovation will expand SIP-linked offerings—from thematic and ESG funds to customised,…

VA Tech Wabag classifies international orders in the $30 million to $75 million range as “large”. The company said that it will design, supply, contract and commission the plant over 14 months.

An industrial component manufacturer, John Cockerill India is involved in the design, manufacturing and commissioning of cold rolling mill complexes, processing lines, and energy transition technology.

The Nifty India Defence index has declined 2.9% in the past month but has gained nearly 20% this year, so far.

Gold prices near all-time highs on MCX and Comex, driven by US Federal Reserve rate cut expectations, weaker dollar, and safe-haven demand. Analysts see further gains into 2026.

Aurobindo Pharma also clarified that the termination, effective December 27, 2025, was reached by mutual consent and is not expected to have any material impact on its broader biosimilars strategy.